Investegate |ABIVAX Announcements | ABIVAX: Abivax's Covid-19 Phase 2b/3 miR-AGE trial with ABX464 declared Research National Priority by the French government's Clinical Trial Council

ABIVAX
Abivax's Covid-19 Phase 2b/3 miR-AGE trial with ABX464 declared Research National Priority by the French government's Clinical Trial Council
DGAP-News: ABIVAX
/ Key word(s): Study
Abivax's Covid-19 Phase 2b/3 miR-AGE trial with ABX464 declared Research National Priority by the French government's Clinical Trial Council
22.12.2020 / 19:30
The issuer is solely responsible for the content of this announcement.
Abivax's Covid-19 Phase 2b/3 miR-AGE trial with ABX464 declared Research National Priority by the French government's Clinical Trial Council
Research National Priority has priority for patient enrollment in clinical trials for an accelerated review and approval process with the French regulatory authorities
Effective Covid-19 treatments very much needed because optimal vaccination coverage of millions of individuals and public acceptance will take time

Related Keywords

United States ,Paris ,France General ,France ,French ,American ,Abivax Covid ,Hartmutj Ehrlich ,Philippe Pouletty ,Research National Priority ,Clinical Trial Council ,Scientific Council ,Euronext ,Clinical Trial ,National Priority ,Euronext Paris ,French Ethics ,Truffle Capital ,Latin American ,ஒன்றுபட்டது மாநிலங்களில் ,பாரிஸ் ,பிரான்ஸ் ஜநரல் ,பிரான்ஸ் ,பிரஞ்சு ,அமெரிக்கன் ,ஆராய்ச்சி தேசிய ப்ரையாரிடீ ,மருத்துவ சோதனை சபை ,அறிவியல் சபை ,மருத்துவ சோதனை ,தேசிய ப்ரையாரிடீ ,பிரஞ்சு நெறிமுறைகள் ,உணவு பண்டமாற்று மூலதனம் ,லத்தீன் அமெரிக்கன் ,